Enfusion (NYSE:ENFN – Get Free Report) will post its quarterly earnings results before the market opens on Tuesday, August 6th. Analysts expect Enfusion to post earnings of $0.06 per share for the quarter. Investors interested in registering for the company’s conference call can do so using this link.
Enfusion (NYSE:ENFN – Get Free Report) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.05). Enfusion had a net margin of 1.40% and a return on equity of 6.60%. The company had revenue of $48.05 million during the quarter, compared to analysts’ expectations of $47.67 million. During the same quarter in the prior year, the business posted $0.04 earnings per share. On average, analysts expect Enfusion to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.
Enfusion Price Performance
Shares of ENFN stock opened at $9.05 on Monday. The stock’s 50-day moving average is $8.87 and its 200 day moving average is $8.98. Enfusion has a 1-year low of $7.52 and a 1-year high of $10.45. The company has a market cap of $1.16 billion, a P/E ratio of 301.67, a PEG ratio of 2.15 and a beta of 0.92.
Analyst Upgrades and Downgrades
Get Our Latest Stock Analysis on Enfusion
Insider Activity at Enfusion
In other news, insider Bronwen Bastone sold 18,241 shares of the business’s stock in a transaction dated Thursday, June 20th. The stock was sold at an average price of $8.11, for a total transaction of $147,934.51. Following the sale, the insider now owns 198,913 shares in the company, valued at $1,613,184.43. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Enfusion news, insider Bronwen Bastone sold 18,241 shares of Enfusion stock in a transaction that occurred on Thursday, June 20th. The shares were sold at an average price of $8.11, for a total transaction of $147,934.51. Following the completion of the sale, the insider now directly owns 198,913 shares in the company, valued at approximately $1,613,184.43. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Deirdre Somers sold 4,629 shares of the stock in a transaction dated Friday, June 14th. The stock was sold at an average price of $8.40, for a total value of $38,883.60. Following the sale, the director now directly owns 43,312 shares in the company, valued at $363,820.80. The disclosure for this sale can be found here. Insiders have sold 36,318 shares of company stock valued at $296,688 in the last ninety days. Corporate insiders own 36.44% of the company’s stock.
Enfusion Company Profile
Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.
See Also
- Five stocks we like better than Enfusion
- Roth IRA Calculator: Calculate Your Potential Returns
- Market Crash? No Problem for DoorDash Stock’s Impressive Earnings
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Snap’s Stock Plummets on Q2 Revenue Guidance Shortfall
- EV Stocks and How to Profit from Them
- Hims & Hers Stock Falls on DexCom Fears: Analysts Predict Rally
Receive News & Ratings for Enfusion Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enfusion and related companies with MarketBeat.com's FREE daily email newsletter.